Live Analyst Rating Changes 26278 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/William Maughan
CS

William Maughan

Clear Street
Wall Street Analyst
★★★☆☆
#1205
on 13Foresight · ranked by our own returns
53%
Success Rate
-5.8%
Average Return
19 of 36 calls profitable · +36.3% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 53% of William Maughan's ratings turned a profit when each position was held for 1 year — averaging -5.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

57 Buy 3 Hold 0 Sell
William's Stock Coverage 26 ratings · 2026-08-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
OCUL
Ocular Therapeutix
 Aug 18, 2026 BUY Strong Buy
+112.1% avg upside
21 analysts
$28.00
138.62% Upside
 · ·
KRRO
Korro Bio
 Aug 07, 2026 BUY Strong Buy
+95.8% avg upside
19 analysts
$18.00
29.06% Upside
 +5.3% ·
BEAM
Beam Therapeutics
 Aug 05, 2026 BUY Strong Buy
+82.6% avg upside
25 analysts
$37.00
27.38% Upside
 +7.4% ·
DNTH
Dianthus Therapeutics
 Aug 05, 2026 BUY Strong Buy
-13.6% avg upside
29 analysts
$130.00
14.34% Upside
 +2.7% ·
SMMT
Summit Therapeutics
 Jul 27, 2026 BUY Buy
+118.9% avg upside
28 analysts
$31.00
136.49% Upside
 +1.9% ·
KRYS
Krystal Biotech
 May 04, 2026 BUY Strong Buy
-22.2% avg upside
20 analysts
$311.00
9.35% Downside
 +16.0% ·
WVE
Wave Life Sciences
 Apr 28, 2026 BUY Strong Buy
+288.2% avg upside
28 analysts
$36.00
564.89% Upside
 -26.7% ·
ANNX
Annexon Biosciences
 Mar 30, 2026 BUY Strong Buy
+157.7% avg upside
14 analysts
$17.00
209.12% Upside
 +6.7% ·
CLLS
Cellectis SA
 Mar 20, 2026 BUY Strong Buy
+533.6% avg upside
16 analysts
$9.00
183.92% Upside
 -8.7% ·
IPSC
Century Therapeutics
 Mar 13, 2026 BUY Strong Buy
+152.6% avg upside
11 analysts
$6.60
212.71% Upside
 -17.9% ·
MOLN
Molecular Partners
 Mar 13, 2026 BUY Strong Buy
+130.9% avg upside
7 analysts
$8.00
84.67% Upside
 -0.2% ·
BNTX
BioNTech SE
 Mar 11, 2026 BUY Strong Buy
+18.9% avg upside
26 analysts
$167.00
47.62% Upside
 +2.1% ·
EDIT
Editas Medicine
 Mar 10, 2026 BUY Buy
+334.7% avg upside
33 analysts
$4.60
41.61% Upside
 +6.8% ·
CRBU
Caribou Biosciences
 Mar 06, 2026 BUY Strong Buy
+580.0% avg upside
12 analysts
$13.00
692.77% Upside
 -13.2% ·
RGNX
RegenXBio
 Mar 06, 2026 BUY Strong Buy
+216.4% avg upside
22 analysts
$45.00
274.41% Upside
 +15.1% ·
DCTH
Delcath Systems
 Feb 26, 2026 BUY Strong Buy
+28.8% avg upside
11 analysts
$27.00
57.48% Upside
 +85.9% ·
CRSP
Crispr Therapeutics AG
 Nov 11, 2025 HOLD Buy
+29.3% avg upside
41 analysts
$50.00
16.41% Downside
 -3.0% ·
IMCR
Immunocore Holdings
 May 23, 2024 HOLD Strong Buy
+75.3% avg upside
22 analysts
$67.00
81.82% Upside
 -35.1% ·
OLMA
Olema Pharmaceuticals
 May 15, 2024 BUY Strong Buy
+245.3% avg upside
16 analysts
$24.00
112.24% Upside
 -52.4% ·
XNCR
Xencor
 May 09, 2024 BUY Strong Buy
+26.5% avg upside
27 analysts
$38.00
38.06% Upside
 -64.6% ·
NKTX
Nkarta
 May 09, 2024 BUY Strong Buy
+634.0% avg upside
16 analysts
$15.00
490.47% Upside
 -69.4% ·
FATE
Fate Therapeutics
 May 09, 2024 BUY Buy
+357.7% avg upside
31 analysts
$9.00
239.65% Upside
 -73.3% ·
MRNA
Moderna
 May 03, 2024 HOLD Hold
-42.6% avg upside
38 analysts
$106.00
39.15% Downside
 -77.9% ·
BCYC
Bicycle Therapeutics
 Feb 20, 2024 BUY Strong Buy
+489.1% avg upside
21 analysts
$60.00
1349.22% Upside
 -47.1% ·
NGNE
Neurogene
 Nov 15, 2022 HOLD Strong Buy
+28.8% avg upside
23 analysts
$5.00
87.25% Downside
 +62.4% ·
BIIB
Biogen
 Sep 05, 2022 BUY Strong Buy
+15.0% avg upside
52 analysts
 — +36.8% ·
🔒 21 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
William Maughan — Frequently Asked Questions
How accurate are William Maughan's stock ratings?
Based on the calls 13Foresight could measure, about 53% of William's ratings were profitable over a one-year hold, with an average return of -5.8% per rating, or +36.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is William ranked on 13Foresight?
William Maughan is currently ranked #1205 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does William cover?
William most recently has ratings on OCUL, KRRO, BEAM, DNTH, SMMT, KRYS, WVE, ANNX, CLLS, IPSC, MOLN, BNTX and 14 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.